Invesco Biotechnology & Genome ETF (PBE)
| Assets | $241.69M |
| Expense Ratio | 0.59% |
| PE Ratio | 15.39 |
| Shares Out | n/a |
| Dividend (ttm) | $0.01 |
| Dividend Yield | 0.02% |
| Ex-Dividend Date | Jun 20, 2023 |
| Payout Ratio | 0.37% |
| 1-Year Return | +1.56% |
| Volume | 7,113 |
| Open | 57.51 |
| Previous Close | 57.48 |
| Day's Range | 57.51 - 58.07 |
| 52-Week Low | 57.07 |
| 52-Week High | 68.50 |
| Beta | n/a |
| Holdings | 32 |
| Inception Date | Jun 23, 2005 |
About PBE
Fund Home PageThe Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering. PBE was launched on Jun 23, 2005 and is issued by Invesco.
Top 10 Holdings
48.00% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 5.55% |
| Vertex Pharmaceuticals Incorporated | VRTX | 5.33% |
| United Therapeutics Corporation | UTHR | 5.29% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.26% |
| Gilead Sciences, Inc. | GILD | 5.26% |
| Biogen Inc. | BIIB | 5.21% |
| BioMarin Pharmaceutical Inc. | BMRN | 5.17% |
| Incyte Corporation | INCY | 4.86% |
| Neurocrine Biosciences, Inc. | NBIX | 3.10% |
| Catalent, Inc. | CTLT | 2.98% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| 2023-06-20 | $0.01407 | 2023-06-23 |
| 2020-03-23 | $0.02898 | 2020-03-31 |
| 2018-09-24 | $0.00207 | 2018-09-28 |
| 2017-06-16 | $0.21532 | 2017-06-30 |
| 2017-03-17 | $0.05552 | 2017-03-31 |
| 2016-12-16 | $0.1208 | 2016-12-30 |
News
PBE Offers Exposure to Surging Catalent Stock
Shares of Catalent (CTLT) are surging on Friday after the contract pharmaceuticals manufacturer provided an update on its full-year outlook and past-due financials. Catalent stock is up over 17% in ea...
Invesco's Rene Reyna on Biotech's Rally and the Potential for Future Growth
Biotech has had a strong rally since June, when fortune for the sector abruptly pivoted after months of underperformance. The sector peaked in early 2021 but struggled to continue the momentum, desp...
Biotech ETFs Benefit From Moderna Dual Booster Shot News
As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot tha...
Could Biotech ETFs Get Another Boost From JNJ News?
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. Thi...
Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be...
Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators ...
Biopharma Here to Stay: The Long-Term Case for the PBE ETF
The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which...
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
2 Biotech Funds Poised for a Healthy Breakout
Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.
3 Health Care ETFs Where Components Are Enduring Downgrades
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
Could Gilead News Be Good For Biotech ETFs?
In a sea of red stocks on Wednesday, as fear grips markets due to another spike in coronavirus cases throughout the country, Gilead Sciences is one of the few bright spots in the stock market.
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
Investors flee Biotech ETFs as they Lag Bull Market
Many biotech ETFs and other funds have fallen sharply off their highs in recent months.
3 Charts That Suggest Now Is the Time to Buy Into Biotech
Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.